Europe Head And Neck Cancer Therapeutics Market Size & Outlook
Related Markets
Europe head and neck cancer therapeutics market highlights
- The Europe head and neck cancer therapeutics market generated a revenue of USD 749.2 million in 2024.
- The market is expected to grow at a CAGR of 11.7% from 2025 to 2033.
- In terms of segment, immunotherapy was the largest revenue generating type in 2024.
- Immunotherapy is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2025 to 2033.
Europe data book summary
| Market revenue in 2024 | USD 749.2 million |
| Market revenue in 2033 | USD 2,018.0 million |
| Growth rate | 11.7% (CAGR from 2025 to 2033) |
| Largest segment | Immunotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
Other key industry trends
- In terms of revenue, Europe region accounted for 33.0% of the global head and neck cancer therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,143.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Head And Neck Cancer Therapeutics Market Scope
Head And Neck Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Clinigen Group | View profile | 1001-5000 | Burton-on-trent, St. Helens, United Kingdom, Europe | http://clinigengroup.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Europe head and neck cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 67.19% in 2024. Horizon Databook has segmented the Europe head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
Europe accounts for a considerable revenue share of the head and neck cancer therapeutics market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced healthcare infrastructure, which is anticipated to boost clinical research prospects in the region significantly.
Moreover, market growth can be attributed to the substantial prevalence of head and neck cancer in the region. According to a research article published in the Oral Oncology journal in October 2022, it is estimated that the prevalence of head and neck cancer in Europe is around 21.8 per 100,000, while the mortality is around 15.6 per 100,000 population.
According to IARC, the number of new lip and oral cavity cancer cases is estimated to increase from 65,279 in 2020 to 71,257 by 2030. Furthermore, the awareness programs conducted by respective governments also support the growth of this market.
Reasons to subscribe to Europe head and neck cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe head and neck cancer therapeutics market databook
-
Our clientele includes a mix of head and neck cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe head and neck cancer therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Europe head and neck cancer therapeutics market size, by country, 2021-2033 (US$M)
Europe Head And Neck Cancer Therapeutics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
